PT - JOURNAL ARTICLE AU - David A. Nace AU - Kevin E. Kip AU - Octavia M. Peck Palmer AU - Michael R. Shurin AU - Katie Mulvey AU - Melissa Crandall AU - April L. Kane AU - Amy Lukanski AU - Paula L. Kip AU - Alan L. Wells TI - Antibody Responses in Elderly Residential Care Persons following COVID-19 mRNA Vaccination AID - 10.1101/2021.04.07.21254925 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.07.21254925 4099 - http://medrxiv.org/content/early/2021/04/10/2021.04.07.21254925.short 4100 - http://medrxiv.org/content/early/2021/04/10/2021.04.07.21254925.full AB - Objective COVID-19 disproportionately impacts older adults residing at long-term care facilities. Data regarding antibody response to COVID-19 vaccines in this population is limited. Our objective was to quantify the presence and magnitude of antibody response in older, vaccinated residents at assisted living, personal care, and independent living facilities.Design A cross-sectional quality improvement study was conducted March 15 – April 1, 2021 in the Pittsburgh region.Setting and Population Participants were volunteers at assisted living, personal care, and independent living facilities, who received mRNA COVID-19 vaccine. Conditions that obviate immune responses were exclusionary criteria.Methods Sera were collected to measure IgG anti-SARS-CoV-2 antibody level with reflex to total anti-SARS-CoV-2 immunoglobulin levels. Descriptive statistics, Pearson correlation coefficients, and multiple linear regression analysis were performed to evaluate relationships between factors potentially associated with antibody levels.Results All participants (N=70) had received two rounds of vaccination for COVID-19 and were found to have antibodies to SARS-CoV-2. There was wide variation in relative levels of antibodies as determined by extinction coefficients. Antibody levels trended lower in male sex, advanced age, steroid medications, and longer length of time from vaccination.Conclusions and Implications Higher functioning long-term care residents mounted detectable antibody responses when vaccinated with COVID-19 mRNA-based vaccines. This study provides preliminary information on level of population risk of assisted living, personal care, and independent living residents which can inform reopening strategies. Data suggests some degree of immunity is present during the immediate period following vaccination. However, protective effects of such vaccination programs remain to be determined in larger studies. Clinical protection is afforded not just by pre-formed antibody levels, but by ongoing adaptive immunity, which is known to be decreased in older individuals. Thus, the implications of these levels of antibodies in preventing COVID-19 disease must be determined by clinical follow-up.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was not a clinical trial.Funding StatementThis work received no external funding. Internal funding from the UPMC Hospital System had no control over the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project underwent review and was granted ethical approval as a quality improvement study by the UPMC Quality Improvement Review Committee (Project ID: 3250), the ethics, regulatory, and legal oversight body for protecting patient/participant rights, confidentiality, consent (including waiver of consent), and the analysis and dissemination of deidentified data within the UPMC system.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data from this analysis is not permissible.